Ocean Biomedical announced that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant funding from the National Institutes of Health (NIH) to advance their groundbreaking malaria vaccine research. In parallel, recent U.S. Food and Drug Administration (FDA) Guidance on lipid-encapsulated vaccines may offer an expedited development pathway for their innovative approach.
Malaria remains a devastating global health challenge, claiming the lives of over 500,000 children annually in sub-Saharan Africa. Despite hundreds of vaccine development efforts, few have succeeded, largely due to ineffective target selection strategies. Dr. Kurtis and his team have taken a novel approach by studying naturally occurring immune responses in children who have developed resistance to malaria.
Through longitudinal studies of children frequently exposed to infected mosquitoes, the researchers identified a unique protein—glutamic acid-rich protein (GARP)—on the surface of malaria-infected red blood cells. Notably, children who naturally resisted severe malaria were found to have developed antibodies against GARP. This discovery, supported by multiple NIH and non-governmental grants, has paved the way for vaccine development.
Also Read: Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
With the support of a $4.6 million non-governmental Foundation grant, Dr. Kurtis’ team is now testing three vaccine candidates in non-human primates. These candidates aim to block the malaria parasite’s ability to enter and exit red blood cells. The research also explores the feasibility of using lipid-encapsulated messenger ribonucleic acid (mRNA) technology as a delivery mechanism.
Building on clinical data from millions of individuals who received lipid-encapsulated mRNA vaccines, the FDA has issued new guidance that could facilitate a faster transition to first-in-human trials. Ocean Biomedical intends to leverage this opportunity, with a potential to initiate human trials as early as 4Q 2025.
In December 2024, Dr. Kurtis secured an additional $3.5 million NIH grant to further identify vaccine targets to protect against severe malaria in children. Commenting on this milestone, Dr. Kurtis stated:
“We are thrilled to receive this additional funding and are encouraged by the emerging data from our human cohort studies. FDA’s new guidance for lipid-encapsulated vaccines will bring us closer to translating years of research into a potential breakthrough malaria vaccine.”
Dr. Chirinjeev Kathuria, Chairman and Co-founder of Ocean Biomedical, added:
“Dr. Kurtis’ work continues to gain significant validation, reinforcing our confidence in the potential of our patented technology. We look forward to further exploring the GARP pathway to develop a vaccine that could have a transformative impact on global health.”
SOURCE: GlobeNewswire